Biopharmaceutical Industry Statement at Gavi, the Vaccine Alliance – Global Vaccine Summit 2020
Geneva, 4 June 2020
Statement delivered by: Thomas Cueni, Director General of IFPMA, the International Federation of Pharmaceutical Manufacturers and Associations.
Today, we face the first global pandemic in living memory. Never before has there been so much hope placed in finding safe and effective vaccines, with the promise that no one is left behind.
IFPMA’s members have worked for 20 years with Gavi to stem the ravages of infectious diseases. NOW they are working at unparalleled speed to develop and build manufacturing capacity and distribution networks to deploy a COVID-19 vaccine in record time. The pace and progress of this work is unprecedented.
We are proud to be a founding partners of the Gavi Alliance and the Vaccines Accelerator and are fully committed to its goal to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.
Be assured, we will deliver on the shared vision to leave no one behind and win the battle against COVID-19 together.
Thank you.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
The value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems (The European House – Ambrosetti)
Over the last decade, the EU economy has experienced slow growth, and it is not expected to grow substantially in the coming years. Additionally, the ongoing demographic and epidemiological transition is increasing pressure on public finances, particularly healthcare and social expenditure. The current permacrisis – encompassing geopolitical and climate-related challenges – exacerbates these issues and...
Read more
Only an urgent shift towards prevention-based healthcare can secure economic stability for EU health systems, experts say
As Governments of EU Member States present their medium-term fiscal structural plans on 20 September, a new report developed by The European House – Ambrosetti, supported by IFPMA and Vaccines Europe, notes that embedding preventative healthcare – in particular immunisation – into EU Member States’ fiscal policies is paramount to ensure the economic sustainability of...
Read morePharmaceutical industry welcomes the launch of Gavi’s new investment round and AVMA
On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.
Read more